MEI Pharma Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced that data from the ongoing Phase I clinical trial of its mitochondrial inhibitor drug candidate ME-344 in patients with refractory solid tumors will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The company said, eight of the 23 patients evaluable for efficacy (35%) achieved disease control, including one confirmed partial response in a patient with refractory small cell lung cancer and seven patients with prolonged stable disease ranging from 8 to 40+ weeks. The maximum tolerated dose was established at 10 mg/kg delivered on a weekly schedule. Dose limiting toxicity of Grade 3 neuropathy was observed at 15 mg/kg and 20 mg/kg.
ME-344 is MEI Pharma's next-generation mitochondrial inhibitor drug candidate and an active metabolite of NV-128, the company's first-generation compound. MEI Pharma owns exclusive worldwide rights to ME-344.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.